These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25461913)

  • 1. Intestinal obstruction in pregnancy by ondansetron.
    Cohen R; Shlomo M; Dil DN; Dinavitser N; Berkovitch M; Koren G
    Reprod Toxicol; 2014 Dec; 50():152-3. PubMed ID: 25461913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum.
    Fejzo MS; MacGibbon K; Mullin P
    Reprod Toxicol; 2015 Nov; 57():207. PubMed ID: 26196894
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event.
    Lebrun C; Chichmanian RM; Peyrade F; Chatel M; Frenay M
    Ann Oncol; 1997 Sep; 8(9):919-20. PubMed ID: 9358948
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).
    Tincello DG; Johnstone MJ
    Postgrad Med J; 1996 Nov; 72(853):688-9. PubMed ID: 8944215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine-type headaches in children receiving chemotherapy and ondansetron.
    Khan RB
    J Child Neurol; 2002 Nov; 17(11):857-8. PubMed ID: 12585731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ondansetron during pregnancy and congenital malformations in the infant.
    Danielsson B; Wikner BN; Källén B
    Reprod Toxicol; 2014 Dec; 50():134-7. PubMed ID: 25450422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report.
    Kasinath NS; Malak O; Tetzlaff J
    Can J Anaesth; 2003 Mar; 50(3):229-31. PubMed ID: 12620943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
    Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
    Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
    Einarson A; Maltepe C; Navioz Y; Kennedy D; Tan MP; Koren G
    BJOG; 2004 Sep; 111(9):940-3. PubMed ID: 15327608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
    Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
    Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
    J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
    ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
    J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy.
    Koren G
    Expert Opin Drug Saf; 2017 Nov; 16(11):1227-1234. PubMed ID: 28749713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
    Slattery J; Quinten C; Candore G; Pinheiro L; Flynn R; Kurz X; Nordeng H
    Br J Clin Pharmacol; 2022 Oct; 88(10):4526-4539. PubMed ID: 35483963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
    Lavecchia M; Chari R; Campbell S; Ross S
    J Obstet Gynaecol Can; 2018 Jul; 40(7):910-918. PubMed ID: 29754832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
    Goldsmith B
    Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
    [No Abstract]   [Full Text] [Related]  

  • 19. Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
    Masarwe S; Shvartsur R; Hadar E; Betesh-Abay B; Peleg N; Azab AN
    Clin Nurs Res; 2023 May; 32(4):705-711. PubMed ID: 36912091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron in pregnancy and risk of adverse fetal outcomes.
    Pasternak B; Svanström H; Hviid A
    N Engl J Med; 2013 Feb; 368(9):814-23. PubMed ID: 23445092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.